Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijantimicag.2020.106142 http://scihub22266oqcxt.onion/10.1016/j.ijantimicag.2020.106142 32853675!7444635!32853675     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Antimicrob+Agents 2020 ; 56 (4): 106142 Nephropedia Template TP {{tp|p=32853675|t=2020. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19 |pdf=|usr=}}{{32853675}} gab.com Text Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19 JO: Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=32853675 #FOAvip This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56% male; median (IQR) age 69 (57-79) years]. All patients received therapy with HCQ in combination with azithromycin (AZM), and 95 (90%) also with lopinavir/ritonavir (LPV/r). Concomitant medications classified as having risk of developing torsades de pointes (TdP) were simultaneously used in 81 patients (77%). Moderate-to-severe QTc prolongation was observed in 14 patients (13%), mostly at Days 3-5 from baseline, with 6 (6%) developing severe prolongation (>500 ms). There was no evidence of TdP arrhythmia or TdP-associated death. Adding LPV/r to HCQ+AZM did not significantly prolong the QTc interval. Multivariable Cox regression revealed that comedications with known risk of TdP (HR = 11.28, 95% CI 1.08-117.41), higher neutrophil-to-lymphocyte (NLR) ratio (HR = 1.10, 95% CI 1.03-1.18 per unit increase) and higher serum hs-cardiac troponin I (HR = 4.09, 95% CI 1.36-12.2 per unit increase) were major contributors to moderate-to-severe QTc prolongation. In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically higher NLR, are conditions requiring careful QTc interval monitoring. Twit Text FOAVip Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19 ????Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=32853675 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32853675 #FOAvip English Wikipedia <ref>{{Cite pmid|32853675}}</ref> Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19 #MMPMID32853675 Padilla S; Telenti G; Guillen L; Garcia JA; Garcia-Abellan J; Ding C; Mora A; Garcia-Pachon E; Gutierrez F; Masia M Int J Antimicrob Agents 2020[Oct]; 56 (4): 106142 PMID32853675show ga This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56% male; median (IQR) age 69 (57-79) years]. All patients received therapy with HCQ in combination with azithromycin (AZM), and 95 (90%) also with lopinavir/ritonavir (LPV/r). Concomitant medications classified as having risk of developing torsades de pointes (TdP) were simultaneously used in 81 patients (77%). Moderate-to-severe QTc prolongation was observed in 14 patients (13%), mostly at Days 3-5 from baseline, with 6 (6%) developing severe prolongation (>500 ms). There was no evidence of TdP arrhythmia or TdP-associated death. Adding LPV/r to HCQ+AZM did not significantly prolong the QTc interval. Multivariable Cox regression revealed that comedications with known risk of TdP (HR = 11.28, 95% CI 1.08-117.41), higher neutrophil-to-lymphocyte (NLR) ratio (HR = 1.10, 95% CI 1.03-1.18 per unit increase) and higher serum hs-cardiac troponin I (HR = 4.09, 95% CI 1.36-12.2 per unit increase) were major contributors to moderate-to-severe QTc prolongation. In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically higher NLR, are conditions requiring careful QTc interval monitoring. |Aged[MESH] |Anti-Infective Agents/*administration & dosage/adverse effects[MESH] |Azithromycin/*administration & dosage/adverse effects[MESH] |Betacoronavirus/*drug effects/immunology/pathogenicity[MESH] |Biomarkers/blood[MESH] |COVID-19[MESH] |Coronavirus Infections/diagnosis/*drug therapy/physiopathology/virology[MESH] |Disease Progression[MESH] |Drug Combinations[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/*administration & dosage/adverse effects[MESH] |Intensive Care Units[MESH] |Long QT Syndrome/chemically induced/diagnosis/physiopathology[MESH] |Lopinavir/*administration & dosage/adverse effects[MESH] |Lymphocytes/pathology/virology[MESH] |Male[MESH] |Middle Aged[MESH] |Neutrophils/pathology/virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/physiopathology/virology[MESH] |Prognosis[MESH] |Proportional Hazards Models[MESH] |Retrospective Studies[MESH] |Ritonavir/*administration & dosage/adverse effects[MESH] |SARS-CoV-2[MESH] |Treatment Outcome[MESH]Predictive factors for cardiac conduction abnormalities with hydroxyc(epmc).pdf DeepDyve Pubget Overpricing